Cyclin A1 expression predicts progression in pT1 urothelial carcinoma of bladder: A tissue microarray study of 149 patients treated by transurethral resection

Histopathology

Volumn 66, Issue 2, 2015, Pages 262-269

  Munari, Enrico ^a   Chaux, Alcides ^a,b   Maldonado, Leonel ^a   Compérat, Eva ^c   Varinot, Justine ^c   Bivalacqua, Trinity J ^a   Hoque, Mohammad O ^a,d   Netto, George J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b Norte University   (Paraguay)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Bladder cancer; Progression; pT1

Indexed keywords

BCG VACCINE; CYCLIN A1; MITOMYCIN; CCNA1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER UROTHELIAL CARCINOMA; CANCER GROWTH; CANCER SURGERY; FOLLOW UP; HUMAN; HUMAN TISSUE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; BIOSYNTHESIS; CANCER STAGING; CARCINOMA, TRANSITIONAL CELL; DISEASE COURSE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; URINARY BLADDER NEOPLASMS; UROLOGIC SURGERY;

CARCINOMA, TRANSITIONAL CELL; CYCLIN A1; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC SURGICAL PROCEDURES;

EID: 84925294097     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12499     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J. Clin. 2013; 63; 11-30.
2. Montie JE, Clark PE, Eisenberger MA et al. Bladder cancer. J. Natl. Compr. Canc. Netw. 2009; 7; 8-39.
3. van Rhijn BW, Burger M, Lotan Y et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 2009; 56; 430- 442.
4. Bertz S, Denzinger S, Otto W et al. Substaging by estimating the size of invasive tumour can improve risk stratification in pt1 urothelial bladder cancer-evaluation of a large hospitalbased single-centre series. Histopathology 2011; 59; 722-732.
5. Brimo F, Wu C, Zeizafoun N et al. Prognostic factors in t1 bladder urothelial carcinoma: the value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum. Pathol. 2013; 44; 95-102.
6. Roupret M, Seisen T, Comperat E et al. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: french national multicenter study with central pathology review. J. Urol. 2013; 189; 2069-2076.
7. Liu D, Liao C, Wolgemuth DJ. A role for cyclin A1 in the activation of mpf and g2-m transition during meiosis of male germ cells in mice. Dev. Biol. 2000; 224; 388-400.
8. Ji P, Agrawal S, Diederichs S et al. Cyclin A1, the alternative atype cyclin, contributes to g1/s cell cycle progression in somatic cells. Oncogene 2005; 24; 2739-2744.
9. Muller-Tidow C, Wang W, Idos GE et al. Cyclin A1 directly interacts with B-myb and cyclin A1/CDK2 phosphorylate B-myb at functionally important serine and threonine residues: tissue-specific regulation of B-myb function. Blood 2001; 97; 2091-2097.
10. Kim J, Kim WJ, Liu Z, Loda M, Freeman MR. The ubiquitinspecific protease USP2A enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 2012; 11; 1123- 1130.
11. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol. Med. 2005; 103; 89-101.
12. Budczies J, Klauschen F, Sinn BV et al. Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. PLoS One 2012; 7; e51862.
13. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus calmette-guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J. Urol. 2003; 169; 96-100.
14. Cheng L, Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J. Clin. Oncol. 1999; 17; 3182-3187.
15. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J. Urol. 1998; 159; 91-94.
16. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma: a prospective cohort study. J. Urol. 1997; 157; 800-803.
17. van der Aa MN, van Leenders GJ, Steyerberg EW et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum. Pathol. 2005; 36; 981-986.
18. Orsola A, Trias I, Raventos CX et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in bcg-treated and BGC-non-treated patients. Eur. Urol. 2005; 48; 231-238.
19. Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol. Oncol. 2013; 31; 849-856.
20. Zuiverloon TC, Nieuweboer AJ, Vekony H, Kirkels WJ, Bangma CH, Zwarthoff EC. Markers predicting response to bacillus Calmette- Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur. Urol. 2012; 61; 128-145.
21. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 2006; 24; 5552-5564.
22. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21WAF1, p27KIP1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am. J. Clin. Pathol. 2004; 122; 444-452.
23. Kruger S, Mahnken A, Kausch I, Feller AC. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur. Urol. 2005; 47; 463-467.
24. Netto GJ. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"? Adv. Anat. Pathol. 2013; 20; 175-203.
25. Liao C, Wang XY, Wei HQ et al. Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc. Natl Acad. Sci. USA 2001; 98; 6853-6858.
26. Wegiel B, Bjartell A, Tuomela J et al. Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis. J. Natl Cancer Inst. 2008; 100; 1022-1036.
27. Maldonado L, Brait M, Michailidi C et al. An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget 2014; 30; 5218-5233.
28. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J. Clin. Oncol. 2008; 26; 5630-5637.
29. Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod. Pathol. 1996; 9; 1035-1039.
30. Selvendiran K, Ahmed S, Dayton A et al. Ho-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol. Cancer Res. 2010; 8; 1188- 1197.